cliccare qui - Farmacia servizi

Curriculum Vitae
Europass
Informazioni personali
Nome(i) / Cognome(i) Giuseppe Cirino
Pagina 1/18 - Curriculum vitae del
Prof. Cirino Giuseppe
I
Indirizzo(i) Dipartimento di Farmacologia Sperimentale, Via Domenico Montesano 49
Telefono(i) 081 678442 Cellulare: Facoltativo (v. istruzioni)
Fax 081-678403
E-mail cirino@unina.it
Cittadinanza Italiana
Data di nascita 19.03.1958
Sesso M
Incarichi Accademici
Ruolo Professore Ordinario
Date 1 Novembre 2006 ad oggi
Lavoro o posizione ricoperti Preside Facoltà Farmacia
Nome e indirizzo del datore di lavoro Università di Napoli Federico II
Date 1
e 1 Novembre 2004 – 31 Ottobre 2006
Lavoro o posizione ricoperti Direttore Dipartimento di Farmacologia Sperimentale
Nome e indirizzo del datore di lavoro Università di Napoli Federico II
Date Ottobre 2003 -1 Novembre 2006
Lavoro o posizione ricoperti Direttore Centro Interdipartimentale di Ricerca Preclinica e Clinica di Medicina Sessuale (CIRMS)
Nome e indirizzo del datore di lavoro Università di Napoli Federico II
Date 2001-2006
Lavoro o posizione ricoperti Membro del Centro Servizi interdipartimentale di Analisi Strumentale (CSIAS)
Nome e indirizzo del datore di lavoro Università di Napoli Federico II
Date 2004 ad oggi
Lavoro o posizione ricoperti Membro del Centro interdipartimentale di di Ricerca in Farmacoeconomia e Farmacoutilizzazione
Nome e indirizzo del datore di lavoro Università di Napoli Federico II

Curriculum Accademico Nov 2004 ad oggi Professore ordinario di Farmacologia e Farmacoterapia I presso la Facoltà di
Farmacia
2001-2004 Professore straordinario BIO/14 in Biotecnologie Farmacologiche presso la Facoltà di
Farmacia.
1999-2003 Ricopre per supplenza di Biotecnologie Farmacologiche I al Corso di Laurea in
Professore associato di Biotecnologie Farmacologiche presso la
Pagina 2/18 - Curriculum vitae del
Prof. Cirino Giuseppe
1998-2001 Facoltà di Farmacia, Corso di Laurea in Chimica e Tecnologia Farmaceutiche
Biotecnologie indirizzo Farmaceutico
1998-2002 Professore associato di Biotecnologie Farmacologiche presso laFacoltà di Farmacia,
Corso di Laurea in Chimica e Tecnologia Farmaceutiche
1994-1998 Ricopre per supplenza l’insegnamento di Biotecnologie Farmacologiche del Corso di
Laurea in Chimica e Tecnologia Farmaceutiche
1994 ad 2003 Iinsegnamento di Biometria presso la Scuola di Specializzazione in Farmacologia
Sperimentale
1989 Vincitore del concorso di ricercatore per la disciplina EO7X ed afferenza al
Dipartimento di Farmacologia Sperime
1993-1998 Ricercatore confermato
Luglio 1987 Dottore di Ricerca in Farmacologia
1984-85 Dottorando di ricerca in Scienze Farmaceutiche curriculum Farmacologia presso il
Dipartimento di Farmacologia Sperimentale della Università degli Studi di Napoli -Federico II
1982-84 Borsista presso l’Ente Farmacologico Italiano
1981-82 Laureato interno presso l’Istituto di Chimica Farmaceutica e Tossicologica della
Facoltà di Farmacia dell’ Università degli Studi di Napoli -Federico II
Curriculum Studiorum 1980 Laurea in Farmacia
1976-1980 Studente Facoltà di farmacia
1976 Diploma di Maturità Classica
Appartenenza a Società scientifiche Societa’ Italiana di Farmacologia
British Pharmacological Society (Fellow)
International Society of Toxinology
Editorial Board British Journal Pharmacology (1999-2004)
General Pharmacology: The vascular System (1999-….)
Journal of Pharmacological and Toxicological Methods (2000 -….)
“Referee” per riviste scientifiche American Journal of Physiology
Biochemical Pharmacology
British Journal Pharmacology
Canadian Journal Physiology and Pharmacology
Europena Journal of Pharmacology
FASEB Journal
FEBS letters
Life Sciences
Thrombosis Research
Thrombosis Haemostasis
P.N.A.S.
Circulation
Ather Thromb Vasc Biol.

Revisore esperto Istituzioni
Internazionali
Pagina 3/18 - Curriculum vitae del
Prof. Cirino Giuseppe
Arthritis Research Campaign
Wellcome Trust
Canadian Institute of Health Research
MIE (Francia)
Alberta Heritage Foundation (Canada)
Health Research Board (Ireland)
Bicentennial Science Foundation (USA/ISRAEL)
Biotechnology and Biological Sciences Research Council (UK)
French National Research Agency
Allegati Allegato 1 (lista delle pubblicazioni)
Firma
Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196
"Codice in materia di protezione dei dati personali (facoltativo)".

Pagina 4/18 - Curriculum vitae del
Prof. Cirino Giuseppe
Publications
1. Cirino G. and Sorrentino L.. 1986. Phospholipase inhibition and prostacyclin generation by gastric
muscularis and mucosa layers. Agents Actions 18:535-537.
2. Pinto A., Cirino G., Meli R., Senatore F and Capasso F. 1987. Inhibitory effects of fungi on aggregation of
rabbit platelets and rat polymorphonuclear leucocytes in vitro. J. Ethnopharmacol. 22: 91-99.
3. Cirino G., Flower R.J., Browning J.L., Sinclair L.K., and Pepinsky R.B. 1987. Recombinant human
lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung. Nature 328:270-272.
4. Cirino G. and Flower R.J. 1987. Human recombinant lipocortin-1 inhibits prostacyclin production by
human umbilical artery in vivo. Prostaglandins 34:59-62.
5. Calignano A., Cirino G., R. Meli, and P. Persico. 1988. Isolation and identification of platelet-activating
factor in UV-irradiated guinea pig skin. J. Pharm. Methods 19:89-91.
6. Wallace J.L., Braquet P., Ibboston G.C., MacNaughton W.K., and Cirino G. 1988. Assessment of the role
of platelet-activating factor in an animal model of inflammatory bowel disease. J. Lipid Mediators 1:13-23.
7. Cirino G., Peers S.H., Flower R.J., Browning J.L. and Pepinsky R.B. 1989. Human recombinant lipocortin
1 has acute local anti-inflammatory properties in the rat paw edema test. Proc. Natl. Acad. Sci U. S. A.
86:3428-3432.
8. Cirino G. and Wallace J.L. 1989. A superfusion bioassay for platelet-activating factor. Can. J. Physiol.
Pharmacol. 67:72-74.
9. MacNaughton W.K., Cirino G., and Wallace J.L. 1989. Endothelium-derived relaxing factor (nitric oxide)
has protective actions in the stomach. Life Sci. 45:1869-1876.
10. Wallace J.L., Cirino G., de Nucci G., McKnight W. and MacNaughton W.K. 1989. Endothelin has potent
ulcerogenic and vasoconstrictor actions in the stomach. Am. J. Physiol. 256:G661-G666.
11. Cirino G., Peers S.H., Wallace J.L. and Flower R.J. 1989. A Study on phospholipase A2-induced oedema
in rat paw. Eur.J.Pharmacol. 166: 505-510.
12. Baydoun, A.R.,. Peers S.H, Cirino G., and Woodward B. 1990. Effects of endothelin-1 on the rat isolated
heart. J. Cardiovascolar Pharmacol. 13: S193-S196.
13. Antunes E., Mariano M., Cirino G., Levi S. and de Nucci G. 1990. Pharmacological characterizationof
polycation-induced rat hind-paw oedema. Br. J. Pharmacol. 101:986-990.
14. Cirino, G. and Flower R.J. 1991. The antiinflammatory activity of human recombinant lipocortin 1. In:
Novel calcium-binding proteins, Ed. Heizman C.W., Springer Verlag Berlin, pp. 568-589.
15. Aquino R., De Feo V., De Simone F., Pizza C. and Cirino G.. 1991. Plant metabolites. New compound and
anti-inflammatory activity of Uncaria Tomentosa. J. Nat. Prod. 54:453-459.

16. Cirino G., Cicala C., Sorrentino L. and Regoli D. 1991. Effect of bradykinin antagonists
N-monomethyl-L-arginine and L-N-nitroarginine on phospholipase A2 induced oedema in rat paw. Gen.
Pharm. 22:801-804.
17. Wallace J.L., Cirino G., Cicala C., Anderson D.W., Argentieri D. and Capetola R.J. 1991. Comparison of
the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs).
Agents Actions 34:247-250.
18. De Tommasis N. , De Simone F., Cirino G., Cicala C., and Pizza C. 1991. Hypoglicemic effects of
sesquiterpene glycosides and polyhydroxylated triterpenoids of Eriobotrya japonica. Planta Medica 57:
414-416.
19. Antunes E., Giraldelo M.M., Cirino G. and G. de Nucci. 1992. Effects of N G -monomethyl-L-arginine and
its D-enantiomer on rat hind paw oedema. In Biology of nitric oxide Ed. Moncada
20. Sautebin L., Cirino G. and M. Di Rosa. 1992. Selective inhibition by antiflammin-2 of thromboxane B2
release from isolated and perfused guinea-pig lung. Med. Inflamm. 1: 251-254.
21. Cirino G., Cicala C., Sorrentino L., Ciliberto G., Arpaia G., Perretti M. and Flower R.J. 1993.
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. Br. J. Pharmacol.
108:573-574.
22. Cirino G., Cicala C., Sorrentino L. and Browning J.L. 1993. Human recombinant non pancreatic secreted
platelet phospholipase A2 has anticoagulant activity in vitro on human plasma. Thromb. Res. 70, 337-342.
23. Cicala C. and Cirino G. 1993. Phospholipase A2 induced hypotension in the rat and its pharmacological
modulation. Gen. Pharm. 24, 1197-1202
24. Cirino G. and. Cicala C. 1993. Human recombinant lipocortin 1 (annexin 1) has anticoagulant activity on
human plasma in vitro. J.Lip.Med. 8, 81-86.
25. Cirino G., Cicala C. and Sorrentino L. 1994. Human recombinant platelet phospholipase A2 exacerbates
poly-L-arginine induced rat paw oedema. Inflammation 18, 59-66.
26. Autore G., Cicala C., Cirino G., Maiello F.M., Mascolo N. and Capasso F. 1994. Essential fatty acid diet
modifies PAF levels in stomach and duodenum of endotoxin treated rats. J.Lip.Med. 9, 145-153.
27. Cirino G., Cicala C., Sorrentino L., Sorrentino R., Browning J.L.
and Page C.P. 1994. Human recombinant secreted phospholipase A2 has antiaggreagtory effect in vivo and
in vitro in rat and guinea pig. Eur. J.Pharmacol. 252, 147-154
28. Cirino G., Cicala C., Sorrentino L., Maiello F.M. and Browning J.L. 1994. Recombinant secreted non
pancreatic phospholipase A2 induces a synovitis-like inflammation in rat air pouch. J. Rheumatol. 21, 824-
829.
29. Girardelo C.M.M., Zappellini E., Muscará M., De Luca I.M.S., Hyslop S., Cirino G., de Nucci G., Antunes
A. 1994. Effect of arginine analogues on rat hind paw oedema and mast cell activation in vitro.
Eur.J.Pharmacol. 257, 87-93
30. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. 1994 A diclofenac derivative
without ulcerogenic properties. Eur. J. Pharmacol. 257, 249-255.
31. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. 1994 Novel NSAID derivatives
with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107, 173-179
Pagina 5/18 - Curriculum vitae del
Prof. Cirino Giuseppe

32. Wallace J.L., Reuter B., Cirino G. 1994 Nitric oxide-releasing NSAIDs: a novel approach for reducing
gastrointestinal toxicity. J. Gastroenterol. Hepatol. 9, S40-S44
33. Landucci E.C.T., Antunes E., Donato J.L., Hyslop S., Maragoni S., Oliveira B., Cirino G. and de Nucci G.
1995. Crotapotin , a polypeptide complexed with phospholipase A2, inhibits carrageenin-induced rat paw
oedema Br. J.Pharmacol. 114, 578-583.
34. Cicala C., Bucci M.R.,. Maraganore J.M. and Cirino G . 1995. Hirulog effect in rat endotoxin shock. Life
Sci. 57, PL307-PL317
35. Reuter B.K., Cirino G. and Wallace J.L.. 1994. Markedly reduced intestinal toxicity of a diclofenac
derivative. Life Sci. 55, PL1-PL8
36. Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., Santagada V., Silipo C., Sorrentino
L. 1994. Synthesis and structure activity relationships of anti-inflammatory 1-methyl-2-(4-X-benzoyl)
imidazole-5- acetic acids. Eur. J. Med. Chem. 29, 381-388.
37. Wallace J.L. and Cirino G. 1994. Gastrointestinal-sparing NSAIDs on the horizon? T.I.P.S. 15, 405-406.
38. Wallace, J.L., Pittman, Q.J., Cirino,G. 1994. Nitric Oxide- releasing NSAIDs: a novel class of GI-sparing
anti-inflammatory drugs. in Novel Molecular Approaches to Anti-Inflammatory theory. Birkhauser Verlag
Basel; pp 1221-129.
39. Wallace J.L., Cirino G., McKnight G.W and Elliott S.N. 1995. Reduction of gastrointestinal injury in
endotoxin shock by flurbiprofen nitroxybutylester. Eur. J.Pharmacol. 280, 63-68.
40. Cirino G., Cicala C., Mancuso F., Baydoun A.R. and Wallace J.L. 1995. Flurbinitroxybutylester: a novel
antiinflammatory drug has enhanced antithrombotic activity. Thromb. Res. 79, 73-81
41. Elliott S.N., McKnight W., Cirino G. and Wallace J.L. 1995. A nitric-oxide releasing nonsteroidal antiinflammatory
drug accelerates gastric ulcer healing in rats. Gastroenterology 109, 524-530.
42. Wallace J.L., McKnight W., Del Soldato P., Baydoun A.R. and. Cirino G.. 1995. Anti-thrombotic effect of
a nitric-oxide releasing, gastric-sparing aspirin derivative. J.Clin.Invest. 96, 2711-271
43. Wallace J.L., Del Soldato P. and G. Cirino. 1995. Development of NSAIDs with reduced gastrointestinal
toxicity. Exp.Opin.Invest.Drugs 4, 613-619.
44. Cirino G., Cicala, C. and de Nucci G. 1995. Human extracellular group II phospholipase A2 and its role in
skin inflammation. in Phospholipase A2 in clinical inflammation, Glaser K.B. and Vadas P. eds. pp 181-
200
45. Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., Santagada V., Silipo C., Sorrentino
L. 1995. Synthesis and anti-inflammatory-analgesic profile of 1-methyl-2-(4-X-benzoyl) imidazole-5carboxylic
acids. Eur.J.Med.Chem. 29, 315-320
46. Cirino G., Cicala C., Bucci M.R., Maraganore J.M.. Sorrentino L. and Stone S.R. 1996. Thrombin
functions as an inflammatory mediator through activation of its receptor. J.Exp.Med. 183, 821-827.
47. Cirino G., Sorrentino R., Cicala C. Sorrentino L. and Pinto A. 1996. Aorta contractions to phenylephrine
of lipopolysaccharide ex vivo treated rats are impaired by indomethacin and the thromboxane antagonist
SQ29,548. J. Lip. Med. 13, 177-187
Pagina 6/18 - Curriculum vitae del
Prof. Cirino Giuseppe

48. Cirino G., Wheeler-Jones C.P.D., Wallace J.L., Del Soldato P. and Baydoun, A.R. 1996. Inhibition of
inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with
gastrointestinal-sparing properties. Br.J.Pharmacol. 117, 1421-1426
49. Cirino G., Misasi M., Loffredo A., Sorrentino L., Caivano P., M. Bucci, Cicala C. 1996. The synovial like
membrane at the bone cement interface in loose total hip replacements contains high levels of extracellular
group II phospholipase A2 Life Sci. 59, PL81-PL86
50. Santagada V., Caliendo G., Perissutti E., Grieco P., Cirino G., Santini A. 1996. Synthesis and biological
activity of lipocortin-5 N-terminus: an attempt to define some structural requirements for activity.
Lett.Peptide Sci. 3: 275-281.
51. Sorrentino R., Cirino G., Calignano A., Mancuso F., Sorrentino L., Andriuoli G., Pinto A. 1996. Increase
in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone, canrenone
and potassium canrenoate. J.Cardiovasc.Pharmacol. 28:519-525.
52. Cirino G., Calignano, A., Andriuoli, G., Sorrentino L. and Pinto A. 1997 Fluoroaluminate induces rapid
release of endothelin-1 in rat perfused mesentery circulation. Gen. Pharm. 28: 459-462
53. Wallace J.L., Del Soldato P., Cirino G. 1997. Nitric oxide-releasing NSAIDs as a potential treatment for
rheumatoid arthritis. Rheumatoid Arth. 1:3-6.
54. Wallace J.L., Del Soldato P., Cirino G. 1997. Nitric oxide-releasing non-steroidal anti-inflammatory drugs:
a new generation of antithrombotics ? Exp.Opin.Invest.Drugs 6:533-538
55. Davies, N.M., Roseth, A.G., Appleyard, C.B., McKnight, W., Del Soldato, P., Calignano, A., Cirino,
G., Wallace, J.L. 1997. NO-naproxen vs naproxen: ulcerogenic , analgesic and anti-inflammatory
effects. Aliment Pharm. Ther.11:69-79
56. Wallace J.L., McKnight W., Wilson T.L., Del Soldato P., Cirino G. 1997. Reduction of hemorrhagic
shock-induced damage by an nitric oxide-releasing aspirin derivative: role of neutrophils Am.J.Physiol.
273:G1246-G1251
57. Cicala C., Bucci M., D’Acquisto F., Parente L., Cirino G. 1997. Sequential release of TNF� and
phospholipase A2 ina a rat model of LPS-induced pleurisy. Med. Inflam. 6:211-215
58. Cirino G., Cicala C., Bucci M., Sorrentino L., Ambrosini G., De Dominicis G., Altieri D.C. 1997.
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of Factor Xa
association with effector cell protease receptor-1 induces acute inflammation in vivo. J. Clin.Invest.
99:2446-2451
59. Wallace J.L., Calignano A., Cirino G. 1997. Potential of new NSAIDs as analgesics. Pain Rev. 4: 230-237.
60. Capasso A., Pinto A., Sorrentino L., Cirino G. 1997. Dexamethasone inhibition of acute opioid physical dependence in vitro
is reverted by anti-lipocortin-1 and mimicked by anti-type II extracellular PLA2 antibodies. Life Sci. 61: PL127-134.
61. Cirino G., Calignano A., Sannicolò F., Primavera A., Del Soldato P Wallace J.L. 1997. NCX4016. Drugs
of the Future 22: 1231-1233.
62. Wallace J.L., Elliott S.N., Del Soldato P., McKnight W., Sannicolo F., Cirino G. 1997. Gastrointestinalsparing
anti-inflammatory drugs: the development of nitric oxide-releasing NSAIDs. Drug Development
Research 42: 144-149
Pagina 7/18 - Curriculum vitae del
Prof. Cirino Giuseppe

63. Landucci E.C., Castro R.C., Pereira M.F., Cintra A.C., Giglio J.R., Marangoni S., Oliveira B., Cirino G.,
Antunes E., de Nucci G. 1998. Mast cell degranulation induced by two phospholipase A2 homologues:
dissociation between enzymatic and biological activity. Eur.J.Pharmacol. 343: 257-263.
64. Garcia –Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papatreopulos A., Sessa W.C. 1998.
Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392:821-824
65. Papatreopulos A., Piccardoni P., Cirino G., Bucci M., Sorrentino R., Cicala C., Kirk J., Zachariou V.,
Sessa W.C, Altieri D.C. 1998. Hypotension and inflammatory cytokine expression triggered by Factor Xanitric
oxide signaling. Proc.Natl.Acad.Sci 95: 4738-4742.
66. Cirino G. 1998. Multiple controls in inflammation. Extracellualr and intracellular phospholipase A2,
inducible and constitutive cyclooxygenase and inducible nitric oxide synthase. Biochem. Pharmacol. 55:
105-111.
67. Cicala C and Cirino G. 1998. Linkage between inflammation and coagulation: an update on the
molecular basis of the crosstalk. Life Sci. 62:1817-1824.
68. Cicala C, Pinto A., Bucci M., Sorrentino R., Walker B., Harriot P., Cruchley A., Howells G. and Cirino
G. (1999) Protease activated receptor –2 involvement in hypotension in normal and endotoxemic rats in
vivo. Circulation 99: 2590-2597.
69. Cicala C., Bucci M., De Dominicis G., Harriot P. Sorrentino L. and Cirino G. (1999) Bronchoconstrictory
effect of thrombin and thrombin receptor activating peptide in guinea pigs in vivo. Br.J.Pharmacol. 126:
478-484.
70. Wallace J.L., Del Soldato P., Cirino G and Muscarà M.(1999) Nitric oxide releasing NSAIDs: GI-safe
antithrombotics. Investigational Drugs in press
71. Saunders M.A., Belvisi M.G., Cirino G., Barnes P.J. and Mitchell J.A.(1999) Mechanisms of
prostaglandin E2 release by intact cells expressing cyclo-oxygenase-2: evidence for a two component
modell. J.Pharm.Exp.Ther. 288:1101-1106
72. Pierro E., Cirino G., Bucci M., Lazzarin N., Andreani C.L., Mancuso S., Lanzone A. and Navarra P.
(1999) Antiphospholipid antibodies inhibit prostaglandin release by decidual cells of early pregnancy:
possible involvement of extracellular secretory phospholipase A2. Fertility Sterility 71: 342-346.
73. Ignarro L.J., Cirino G., Casini A., Napoli C. (1999) Nitric oxide as a signalling molecule in the vascular
system: an overview. J. Cardiovasc. Pharmacol. 34: 879-886
74. Napoli C., Cicala C., D’Armiento F.P., Roviezzo F., Somma P., de Nigris F., Zuliani P., Bucci M.,
Aleotti L., Casini A., Franconi F., Cirino G. (1999) Benficial effects of ACE-inhibition with zofenopril
on plaque formation and low-density lipoprotein in watanabe heritable hypelipidemic rabbits. Gen.
Pharmacol. 33:467-477
75. Fiorucci S., Santucci L., Federici B., Antonelli E., Distrutti E., Morelli O., Di Renzo G., Coata G.,
Cirino G., Del Soldato P., Morelli A. (1999) Nitric oxide releasing NSAIDs inhibit interleukin 1�
converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by
TNF�. Aliment. Pharmacol. Ther. 13:421-435.
76. Wallace JL, Del Soldato P, Cirino G, Muscara MN. Nitric oxide Releasing NSAIDs: GI-safe
antithrombotics. IDrugs. 1999 Apr;2(4):321-6
Pagina 8/18 - Curriculum vitae del
Prof. Cirino Giuseppe

77. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. In vivo delivery of
the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation.Nat Med.
2000 Dec;6(12):1362-7.
78. Ianaro A., Cicala C., Calignano A., Koteliansky V., Gotwals P., Bucci M., Gerli R., Santucci L.,
Fiorucci S., Cirino G. (2000) Anti-very late antigen-1 monoclonal antibody modulates the development
of secondary lesion and T cell response in experimental arthritis. Lab.Invest. 80:73-80
79. Landucci EC. Toyama M., Marangoni S., Oliveira B., Cirino G., Antunes E., de Nucci G. (2000) Effect
of crotapotin and heparin on the rat paw oedema induced by different secretory phospholipases A2.
Toxicon 38: 199-208.
80. Napoli C., Cicala C., Wallace J.L., de Nigris F., Santagada V., Caliendo G., Franconi F., Ignarro L.J.,
Cirino G. (2000) Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the
rat heart. Proc.Natl.Acad. Sci. 97:3678-3683
81. Cirino G., Napoli C., Bucci M., Cicala C. (2000) Inflammation-coagulation network: are serine
protease the knot? T.I.P.S. 21:170-172
82. Carla Cicala, Angela Ianaro, Stefano Fiorucci, Antonio Calignano, Mariarosaria Bucci, Roberto Gerli,
Luca Santucci, John L. Wallace, and Giuseppe Cirino (2000) NO-naproxen modulates inflammation,
nociception and downregulates T cell response in rat Freund's adjuvant arthritis Br. J. Pharmacol.;130
1399-1405
83. Bucci M, Roviezzo F, Cicala C, Sessa WC, Cirino G. (2000) Geldanamycin, an inhibitor of heat shock
protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with
glucocorticoid receptor in vivo.Br J Pharmacol. 131:13-16.
84. Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, Alfieri C,
Sorrentino L, Pinto A. (2000) Effect of spironolactone and its metabolites on contractile property of
isolated rat aorta rings.J Cardiovasc Pharmacol.36:230-5.
85. Muscara MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL (2000) Antihypertensive
properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats.Am J Physiol
Heart Circ Physiol.279 H528-35
86. Mirone V, Sorrentino R, di Villa Bianca R, Imbimbo C, Palmieri A, Fusco F, Tajana G, Cirino G.A
standardized procedure for using human corpus cavernosum strips to evaluate drug activity.J Pharmacol
Toxicol Methods. 2000 Nov-Dec;44(3):477-82.
87. Fiorucci S, Santucci L, Cirino G, Mencarelli A, Familiari L, Soldato PD, Morelli A. IL-1 beta
converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory
mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J Immunol. 2000;165:5245-
54.
88. Napoli C, Pinto A, Cirino G.Pharmacological modulation, preclinical studies, and new clinical
features of myocardial ischemic preconditioning. Pharmacol Ther. 2000 88:311-31.
89. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N,
Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL.Proteinase-activated receptor-2 and
hyperalgesia: A novel pain pathway. Nat Med. 2001; 7:821-6.
90. Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G. Pharmacological dissection
of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized
rats.FASEB J. 2001; 15:1433-5.
Pagina 9/18 - Curriculum vitae del
Prof. Cirino Giuseppe

91. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing:
role of endostatin and vascular endothelial growth factor release.Proc Natl Acad Sci U S A. 2001;98
:6470-5.
92. Cicala C, Spina D, Keir SD, Severino B, Meli R, Page CP, Cirino G.Protective effect of a PAR2activating
peptide on histamine-induced bronchoconstriction in guinea-pig.Br J Pharmacol. 2001,
132:1229-34.
93. Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V V, Condorelli M, Pinto A, Ignarro LJ.
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc
Natl Acad Sci U S A. 2001; 98:2860-2864.
94. Randazzo A, Bifulco G, Giannini C, Bucci M, Debitus C, Cirino G, Gomez-Paloma L. Halipeptins A
and B: Two Novel Potent Anti-inflammatory Cyclic Depsipeptides from the Vanuatu Marine Sponge
Haliclona species. J Am Chem Soc. 2001, 123:10870-10876.
95. Caliendo G, Santagada V, Perissutti E, Severino B, Fiorino F, Warner TD, Wallace JL, Ifa DR,
Antunes E, Cirino G, de Nucci G. Synthesis of substituted benzamides as anti-inflammatory agents that
inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. Eur J Med Chem. 2001, 36
:517-30.
96. Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G. Pharmacological dissection
of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats.
FASEB J. 2001, 15:1433-5.
97. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing:
role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A. 2001, 98:
6470-5.
98. Meli R, Mattace Raso G, Cicala C, Esposito E, Fiorino F, Cirino G. Thrombin and PAR-1 acitvating
peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. J Neurochem. 2001;79:556-
563.
99. Santagada V, Caliendo G, Severino B, Perissutti E, Fiorino F, Cicala C, De Filippis V, Cirino G.
Minimal structural requirements for agonist activity of PAR-2 activating peptides. Bioorg Med Chem
Lett. 2002; 12:21-24.
100. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase.
A new avenue in anti-inflammatory therapy? Biochem Pharmacol. 2001 62:1433-8.
101. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL,
Morelli A, Cirino G. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina
propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A. 2001, 98:13936-41.
102. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G. 17-beta-oestradiol-induced vasorelaxation in
vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol.
2002,135:1695-1700.
103. Rossoni G, Muscara MN, Cirino G, Wallace JL. Inhibition of cyclo-oxygenase-2 exacerbates
ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol. 2002,135:1540-6.
Pagina 10/18 - Curriculum vitae del
Prof. Cirino Giuseppe

104. Maffia P, Ianaro A, Sorrentino R, Lippolis L, Maiello FM, del Soldato P,Ialenti A, Cirino G.
Beneficial effects of NO-releasing derivative of flurbiprofen (HCT-1026) in rat model of vascular injury
and restenosis.Arterioscler Thromb Vasc Biol. 2002, 22:263-7.
105. Meli R, Antonelli E, Cirino G. Analgesia and cyclo-oxygenase inhibitors.Dig Liver Dis. 2001,
33 Suppl 2:S8-11.Cirino G, Santagada V, Caliendo G. The nitric oxide related therapeutic phenomenon:
a challenging task. Curr Pharm Des. 2002, 8:233-9.
106. Saviola G, Abdi Ali L, Rossoni P, Campostrini L, Coppini A, Gori M, Ianaro, A, Bucci M, de
Nucci G, Cirino G.. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying
antirheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol. 2002; 20:373-8.
107. Napoli C, De Nigris F, Cicala C, Wallace JL, Caliendo G, Condorelli M, Santagada V, Cirino
G. Protease-activated receptor-2 activation improves efficiency of experimental ischemic
preconditioning. Am J Physiol Heart Circ Physiol. 2002, 282: H2004-H2010.
108. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G. 17-beta-oestradiol-induced vasorelaxation in
vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism.Br J Pharmacol. 2002,
135:1695-700.
109. Fiorucci S, Mencarelli A, Palazzetti B, Sprague AG, Distrutti E, Morelli A, Novobrantseva TI,
Cirino G, Koteliansky VE, de Fougerolles AR. Importance of innate immunity and collagen binding
integrin alpha1beta1 in TNBS-induced colitis. Immunity. 2002, 17:769-80.
110. Cicala C, Morello S, Vellecco V, Severino B, Sorrentino L, Cirino G. Basal nitric oxide
modulates vascular effects of a peptide activating protease-activated receptor 2.Cardiovasc Res. 2003,
60:431-7.
111. Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, Perretti M.
Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J
Immunol. 2003,171:3245-52.
112. Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G, Wallace JL. Evidence
that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial
adherence in response to aspirin. Br J Pharmacol. 2003,139:1351-9.
113. Cirino G. Nitric oxide releasing drugs: from bench to bedside.Dig Liver Dis. 2003; 35 Suppl
2:S2-8.
114. Fiorucci S, Distrutti E, Federici B, Palazzetti B, Baldoni M, Morelli A, Cirino G. PAR-2
modulates pepsinogen secretion from gastric-isolated chief cells.Am J Physiol Gastrointest Liver
Physiol. 2003, 285:G611-20.
115. Cirino G, Sorrentino R, di Villa Bianca R, Popolo A, Palmieri A, Imbimbo C, Fusco F, Longo
N, Tajana G, Ignarro LJ, Mirone V. Involvement of beta 3-adrenergic receptor activation via cyclic
GMP- but not NO-dependent mechanisms in human corpus cavernosum function.Proc Natl Acad Sci U
S A. 2003,100:5531-6.
116. Esposito F, Chirico G, Montesano Gesualdi N, Posadas I, Ammendola R, Russo T, Cirino G,
Cimino F. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase
receptor phosphorylation and requires SRC activity. J Biol Chem. 2003, 278:20828-34.
117. Cirino G, Fiorucci S, Sessa WC. Endothelial nitric oxide synthase: the Cinderella of
inflammation? Trends Pharmacol Sci. 2003, 24:91-5.
Pagina 11/18 - Curriculum vitae del
Prof. Cirino Giuseppe

118. Roviezzo F, Del Galdo F, Abbate G, Bucci M, D'Agostino B, Antunes E, De Dominicis G,
Parente L, Rossi F, Cirino G, De Palma R. Human eosinophil chemotaxis and selective in vivo
recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci U S A. 2004 ;101:11170-11175.
119. Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, Cirino G. Carrageenaninduced
mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide
cyclooxygenase-2 expression. Br J Pharmacol. 2004; 142:331-338.
120. Wallace JL, Rizzo G, Cirino G, Del Soldato P, Fiorucci S. Enhanced anti-inflammatory
potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB. J Pharmacol
Exp Ther. 2004; 310:1096-1102.
121. Napoli C, de Nigris F, Wallace JL, Hollenberg MD, Tajana G, De Rosa G, Sica V, Cirino G.
Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic
lesions. J Clin Pathol. 2004; 57:513-516.
122. Pieretti S, Di Giannuario A, De Felice M, Perretti M, Cirino G. Stimulus-dependent specificity
for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for
formylated peptides. Pain. 2004; 109: 52-63.
123. Bucci M, Roviezzo F, Brancaleone V, Lin MI, Di Lorenzo A, Cicala C, Pinto A, Sessa WC,
Farneti S, Fiorucci S, Cirino G. Diabetic mouse angiopathy is linked to progressive sympathetic
receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol. 2004;
24 :721-726.
124. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G,
Santagada V, Morelli A, Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role
of proteinase receptors in stellate cell activation. Hepatology. 2004; 39:365-75.
125. Wallace JL, Muscara MN, de Nucci G, Zamuner S, Cirino G, del Soldato P, Ongini E. Gastric
tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen
derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2propenoic
acid 4-nitrooxy butyl ester]. J Pharmacol Exp Ther. 2004; 309: 626-633.
126. Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. Nitric oxide (NO)releasing
naproxen (HCT-3012) interactions with aspirin in gastric mucosa of arthritic rats reveals a role
for aspirin-triggered lipoxin, prostaglandins and NO in gastric protection. J Pharmacol Exp Ther. 2004;
311: 1264-1271.
127. Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M,
Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. A role for
proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest. 2004; 114: 1444-1456.
128. Buresi MC, Vergnolle N, Sharkey KA, Keenan CM, Andrade-Gordon P, Cirino G, Cirillo D,
Hollenberg MD, MacNaughton WK. Activation of proteinase-activated receptor-1 inhibits neurallyevoked
chloride secretion in the mouse colon in vitro. Am J Physiol Gastrointest Liver Physiol. 2005;
288: G337-345.
129. Bucci M, Roviezzo F, Posadas I, Yu J, Parente L, Sessa WC, Ignarro LJ, Cirino G. Endothelial
nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc
Natl Acad Sci U S A. 2005; 102:904-8.
Pagina 12/18 - Curriculum vitae del
Prof. Cirino Giuseppe

130. d'Emmanuele di Villa Bianca R, Sorrentino R, Roviezzo F, Imbimbo C, Palmieri A, De
Dominicis G, Montorsi F, Cirino G, Mirone V. Peripheral relaxant activity of apomorphine and of a
D1 selective receptor agonist on human corpus cavernosum strips. Int J Impot Res 2005; 17: 127-133
131. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Antonelli E, Roviezzo F, Morelli
A, Wallace JL, Cirino G, Fiorucci S. Evidence that hydrogen sulfide exerts antinociceptive effects in
the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther. 2006; 316:325-35.
132. Bucci M, Roviezzo F, Cirino G. Protease-activated receptor-2 (PAR(2)) in cardiovascular
system. Vascul Pharmacol. 2005; 43:247-53
133. Roviezzo F, Bucci M, Brancaleone V, Di Lorenzo A, Geppetti P, Farneti S, Parente L,
Lungarella G, Fiorucci S, Cirino G. Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in
Diabetes. Arterioscler Thromb Vasc Biol. 2005; 25:2349-54.
134. Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, Tarantini F, Ketabchi
S, Cirino G, Hollenberg MD, Geppetti P, Santucci M Expression of protease-activated receptors 1 and
2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005; 36:676-85.
135. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, Papapetropoulos
A. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage.J Pharmacol Exp Ther.
2005; 314:738-44.
136. Bucci M, Roviezzo F, Posadas I, Yu J, Parente L, Sessa WC, Ignarro LJ, Cirino G.
Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in
vivo. Proc Natl Acad Sci U S A. 2005; 102:904-8.
137. Perissutti E, Fiorino F, Renner C, Severino B, Roviezzo F, Sautebin L, Rossi A, Cirino G, Santagada
V, Caliendo G. Synthesis of 2-methyl-3-indolylacetic derivatives as anti-inflammatory agents that
inhibit preferentially cyclooxygenase 1 without gastric damage. J Med Chem. 2006; 49:7774-80.
138. Martino L, Virno A, Randazzo A, Virgilio A, Esposito V, Giancola C, Bucci M, Cirino G, Mayol L.
A new modified thrombin binding aptamer containing a 5'-5'inversion of polarity site. Nucleic Acids
Res. 2006;34:6653-62.
139. Naldini A, Morena E, Filippi I, Pucci A, Bucci M, Cirino G, Carraro F.
Thrombin inhibits IFN-gamma production in human peripheral blood mononuclear cells by promoting a
Th2 profile. J Interferon Cytokine Res. 2006;26:793-9.
140. Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P,
Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. A
role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest. 2006l;116:2056.
141. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an
endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006; 20:2118-20.
142. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino
G, Wallace JL, Fiorucci S. 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl
ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects
in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006; 319:447-58.
143. Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the
gastrointestinal tract and liver. Gastroenterology. 2006;131:259-71.
Pagina 13/18 - Curriculum vitae del
Prof. Cirino Giuseppe

144. Cirino G, Vergnolle N. Proteinase-activated receptors (PARs): crossroads
between innate immunity and coagulation. Curr Opin Pharmacol. 2006;6:428-34.
145. Cirino G, Distrutti E, Wallace JL. Nitric oxide and inflammation. Inflamm
Allergy Drug Targets. 2006; 5:115-9.
146. Nicolaou KC, Lizos DE, Kim DW, Schlawe D, de Noronha RG, Longbottom DA,
Rodriquez M, Bucci M, Cirino G. Total synthesis and biological evaluation of halipeptins A and D and
analogues. J Am Chem Soc. 2006; 128:4460-70.
147. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol
Ther. 2006;111:400-23.
148. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S, Leoncini G, Cirino G,
Geppetti P, Santucci M. Evidence for differential expression of Notch receptors and their ligands in
melanocytic nevi and cutaneous malignant melanoma. Mod Pathol. 2006; 19:246-54.
149. Saviola G, Benucci M, Cirino G. Comments on: Effects of clarithromycin in patients with
active rheumatoid arthritis.Curr Med Res Opin. 2007;23:2763-2764.
150. D'Agostino B, Roviezzo F, De Palma R, Terracciano S, De Nardo M, Gallelli L, Abbate GF,
D'Aiuto E, Russo M, Cirino G, Rossi F. Activation of protease-activated receptor-2 reduces airways
inflammation in experimental allergic asthma. Clin Exp Allergy. 2007; 37:1436-43.
151. Naldini A, Ardinghi C, Massi D, Santucci M, Franchi A, Tarantini F, Geppetti, P, Cirino G,
Carraro F. A ribonuclease protection assay-based approach for analysis of angiogenic gene expression
in archival tissues. Diagn Mol Pathol. 2007 ; 16:147-52.
152. Materazzi S, Pellerito S, Di Serio C, Paglierani M, Naldini A, Ardinghi C, Carraro F,
Geppetti P, Cirino G, Santucci M, Tarantini F, Massi D. Analysis of protease-activated receptor-1 and -
2 in human scar formation. J Pathol. 2007; 212: 440-9.
153. Virno A, Randazzo A, Giancola C, Bucci M, Cirino G, Mayol L. A novel thrombin binding
aptamer containing a G-LNA residue. Bioorg Med Chem. 2007; 15: 5710-8.
154. Ketabchi S, Massi D, Ficarra G, Rubino I, Franchi A, Paglierani M, Simoni A, Capodiferro
S, Favia G, Maiorano E, Tarantini F, Cirino G, Santucci M. Expression of protease-activated receptor-
1 and -2 in orofacial granulomatosis.Oral Dis. 2007; 13:419-25.
155. Di Serio C, Pellerito S, Duarte M, Massi D, Naldini A, Cirino G, Prudovsky I, Santucci M,
Geppetti P, Marchionni N, Masotti G, Tarantini F. Protease-activated receptor 1-selective antagonist
SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1independent
mechanism. Basic Clin Pharmacol Toxicol. 2007; 101:63-9.
156. Roviezzo F, Cuzzocrea S, Di Lorenzo A, Brancaleone V, Mazzon E, Di Paola R, Bucci M,
Cirino G. Protective role of PI3-kinase-Akt-eNOS signalling pathway in intestinal injury associated
with splanchnic artery occlusion shock. Br J Pharmacol. 2007; 151:377-83.
157. Saviola G, Abdi Ali L, Shams Eddin S, Coppini A, Cavalieri F, Campostrini L, Sacco S,
Bucci M, Cirino G, Rossini M. Compared clinical efficacy and bone metabolic effects of low-dose
deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized
pilot study. Rheumatology . 2007; 46:994-8.
Pagina 14/18 - Curriculum vitae del
Prof. Cirino Giuseppe

158. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E, Santucci L,
Cirino G, Wallace JL. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine
(ATB-429) in a mouse model of colitis.Br J Pharmacol. 2007; 150:996-1002
159. Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, De Nardo M, Orlotti D,
De Palma R, Rossi F, D'Agostino B, Cirino G. Sphingosine-1-phosphate/sphingosine kinase pathway is
involved in mouse airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2007; 36:757-62.
160. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S. Gastrointestinal safety and
anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.
Gastroenterology. 2007; 132:261-71.
161. Coppola T, Varra M, Oliviero G, Galeone A, D'Isa G, Mayol L, Morelli E, Bucci MR, Vellecco V,
Cirino G, Borbone N. Synthesis, structural studies and biological properties of new TBA analogues
containing an acyclic nucleotide. Bioorg Med Chem. 2008; 16 (17):8244-53.
162. Brancaleone V, Roviezzo F, Vellecco V, De Gruttola L, Bucci M, Cirino G. Biosynthesis of H2S is
impaired in non-obese diabetic (NOD) mice. Br J Pharmacol. 2008; 155:673-80.
163. Bucci M, Roviezzo F, Brancaleone V, Di Lorenzo A, Evangelista S, Gori M, Cirino G. ACEinhibition
ameliorates vascular reactivity and delays diabetes outcome in NOD mice. Vascul Pharmacol.
2008; 49:84-90.
164. Lucattelli M, Lunghi B, Fineschi S, Mirone V, d'Emmanuele di Villa Bianca R,Longo N, Imbimbo C,
De Palma R, Sorrentino R, Lungarella G, Cirino G. A new mouse model of Peyronie's disease: an
increased expression of hypoxia-inducible factor-1 target genes during the development of penile
changes. Int J Biochem Cell Biol. 2008; 40:2638-48.
165. Severino B, Fiorino F, Perissutti E, Frecentese F, Cirino G, Roviezzo F, Santagada V, Caliendo G.
Synthesis and pharmacological evaluation of peptide-mimetic protease-activated receptor-1 antagonists
containing novel heterocyclic scaffolds. Bioorg Med Chem. 2008; 16:6009-20.
166. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, De Palma
R, Ignarro LJ, Cirino G. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle
relaxation. Proc Natl Acad Sci U S A. 2009 ; 106(11):4513-8.
167. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone V, Ciro I, Cirino G.
Hydrogen Sulphide Is Involved in Testosterone Vascular Effect. Eur Urol. 2009; 56:378-383.
d'Emmanuele di Villa Bianca R, Sorrentino R, Mirone V, Cirino G. Hydrogen sulfide and erectile
function: a novel therapeutic target. Nat Rev Urol. 2011; 8:286-9.
168. Roviezzo F, Brancaleone V, De Gruttola L, Vellecco V, Bucci M, D'Agostino B, Cooper D,
Sorrentino R, Perretti M, Cirino G. Sphingosine-1-phosphate modulates vascular permeability and cell
recruitment in acute inflammation in vivo. JPharmacol Exp Ther. 2011;337:830-7.
169. Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M. Evidence for an anti-inflammatory
loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and
operative in the inflamed microvasculature. J Immunol. 2011; 186:4905-14.
170. Bucci M, Cirino G. Hydrogen sulphide in heart and systemic circulation. Inflamm Allergy Drug
Targets. 2011; 10:103-8.
Pagina 15/18 - Curriculum vitae del
Prof. Cirino Giuseppe

171. d'Emmanuele di Villa Bianca R, Sorrentino R, Coletta C, Mitidieri E, Rossi A, Vellecco V, Pinto A,
Cirino G, Sorrentino R. Hydrogen sulfide-induced dual vascular effect involves arachidonic acid
cascade in rat mesenteric arterial bed. J Pharmacol Exp Ther. 2011; 337:59-64.
172. Renshaw D, Montero-Melendez T, Dalli J, Kamal A, Brancaleone V, D'Acquisto F, Cirino G, Perretti
M. Downstream gene activation of the receptor ALX by the agonist annexin A1. PLOS One. 2010;5:
12771
173. di Villa Bianca R, Coletta C, Mitidieri E, De Dominicis G, Rossi A, Sautebin L, Cirino G, Bucci M,
Sorrentino R. Hydrogen sulphide induces mouse paw oedema through activation of phospholipase A2.
Br J Pharmacol. 2010; 161:1835-42.
174. De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucattelli M. Pulmonary hypertension in
smoking mice over-expressing protease-activated receptor-2. Eur Respir J. 2011; 37:823-34.
175. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancaleone
V, Cirino G. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler
Thromb Vasc Biol. 2010; 30:1998-2004.
176. Caliendo G, Cirino G, Santagada V, Wallace JL. Synthesis and biological effects of hydrogen sulfide
(H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem. 2010; 53:6275-86.
177. Cirino G, Severino B. Thrombin receptors and their antagonists: an update on the patent literature.
Expert Opin Ther Pat. 2010; 20:875-84.
178. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphidereleasing
derivative of naproxen (ATB-346). Br J Pharmacol. 2010; 159:1236-46.
179. Saviola G, Benucci M, Abdi-Ali L, Baiardi P, Manfredi M, Bucci M, Cirino G.Clarithromycin in
adult-onset Still's disease: a study of 6 cases. Rheumatol Int.2010; 30:555-60.
180. Costantino V, Fattorusso E, Mangoni A, Perinu C, Cirino G, De Gruttola L,Roviezzo F. Tedanol: a
potent anti-inflammatory ent-pimarane diterpene from the Caribbean Sponge Tedania ignis. Bioorg Med
Chem. 2009; 17:7542-7.
181. d'Emmanuele di Villa Bianca R, Cirino G, Mitidieri E, Coletta C, Grassia G, Roviezzo F, Grieco P,
Novellino E, Imbimbo C, Mirone V, Sorrentino R. Urotensin II: a novel target in human corpus
cavernosum. J Sex Med. 2010; 7:1778-86.
182. Mirone V, d'Emmanuele di Villa Bianca R, Mitidieri E, Imbimbo C, Fusco F,Verze P, Vitale DF,
Sorrentino R, Cirino G. Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase
type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study.
Eur Urol. 2009; 56:1067-73.
183. D'Agostino B, Polverino M, Cirino G, Lombardi A, Grassi B, Sullo N,Santoriello C, Polverino F,
Orlotti D, Matteis M, Rossi F. Exercise capacity and cytochrome oxidase activity in muscle
mitochondria of COPD patients. Respir Med.2010; 104:83-90.
184. Di Lorenzo A, Fernández-Hernando C, Cirino G, Sessa WC. Akt1 is critical for acute inflammation
and histamine-mediated vascular leakage. Proc Natl Acad Sci US A. 2009; 106:14552-7.
Pagina 16/18 - Curriculum vitae del
Prof. Cirino Giuseppe

185. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, De Palma
R, Ignarro LJ, Cirino G. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle
relaxation. Proc Natl Acad Sci U S A. 2009 ; 106:4513-4518.
186. Roviezzo F, D'Agostino B, Brancaleone V, De Gruttola L, Bucci M, De Dominicis G, Orlotti D,
D'Aiuto E, De Palma R, Rossi F, Sorrentino R, Cirino G. Systemic administration of sphingosine-1phosphate
increases bronchial hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol. 2010;
42:572-7.
187. Caliendo G, Cirino G, Santagada V, Wallace JL. Synthesis and biological effects of hydrogen sulfide
(H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem. 2010; 53:6275-86.
188. Cirino G, Severino B. Thrombin receptors and their antagonists: an update on the patent literature.
Expert Opin Ther Pat. 2010; 20:875-84.
189. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphidereleasing
derivative of naproxen (ATB-346). Br J Pharmacol. 2010; 159:1236-46.
190. d'Emmanuele di Villa Bianca R, Cirino G, Mitidieri E, Coletta C, Grassia G, Roviezzo F, Grieco P,
Novellino E, Imbimbo C, Mirone V, Sorrentino R. Urotensin II: a novel target in human corpus
cavernosum. J Sex Med. 2010; 7:1778-86.
191. Renshaw D, Montero-Melendez T, Dalli J, Kamal A, Brancaleone V, D'Acquisto F,
Cirino G, Perretti M. Downstream gene activation of the receptor ALX by the agonist annexin A1.
PLoS One. 2010;5 (9). pii: e12771.
192. di Villa Bianca R, Coletta C, Mitidieri E, De Dominicis G, Rossi A, Sautebin L, Cirino G, Bucci M,
Sorrentino R. Hydrogen sulphide induces mouse paw oedema through activation of phospholipase A2.
Br J Pharmacol. 2010;161:1835-42
193. Marazioti A, Bucci M, Coletta C, Vellecco V, Baskaran P, Szabó C, Cirino G, Marques AR,
Guerreiro B, Gonçalves AM, Seixas JD, Beuve A, Romão CC, Papapetropoulos A. Inhibition of nitric
oxide-stimulated vasorelaxation by carbon monoxide-releasing molecules. Arterioscler Thromb Vasc
Biol. 2011;31:2570-6.
194. di Villa Bianca R, Mitidieri E, Mirone V, Fusco F, Imbimbo C, Cirino G, Sorrentino R. An ex vivo
standardized assay to measure human platelet cGMP. J Pharmacol Toxicol Methods. 2011; 64:164-7.
195. d'Emmanuele di Villa Bianca R, Sorrentino R, Mirone V, Cirino G. Hydrogen sulfide and erectile
function: a novel therapeutic target. Nat Rev Urol. 2011;8:286-9.
196. Roviezzo F, Brancaleone V, De Gruttola L, Vellecco V, Bucci M, D'Agostino B, Cooper D,
Sorrentino R, Perretti M, Cirino G. Sphingosine-1-phosphate modulates vascular permeability and cell
recruitment in acute inflammation in vivo. J Pharmacol Exp Ther. 2011;337:830-7.
197. Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M. Evidence for an anti-inflammatory
loop centered on polymorphonuclear leukocyte formyl peptide receptor 2 / lipoxin A4 receptor and
operative in the inflamed microvasculature. J Immunol. 2011; 186: 4905-14.
198. Bucci M, Cirino G. Hydrogen sulphide in heart and systemic circulation. nflamm Allergy Drug
Targets. 2011; 10:103-8.
Pagina 17/18 - Curriculum vitae del
Prof. Cirino Giuseppe

199. d'Emmanuele di Villa Bianca R, Sorrentino R, Coletta C, Mitidieri E, Rossi A, Vellecco V, Pinto A,
Cirino G, Sorrentino R. Hydrogen sulfide-induced dual vascular effect involves arachidonic acid
cascade in rat mesenteric arterial bed. J Pharmacol Exp Ther. 2011 337:59-64.
200. De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucattelli M Pulmonary hypertension in
smoking mice over-expressing protease-activated receptor-2. Eur Respir J. 2011;37:823-34.
201. Bucci M, Cigliano L, Vellecco V, D'Andrea LD, Ziaco B, Rossi A, Sautebin L, Carlucci A, Abrescia
P, Pedone C, Ianaro A, Cirino G. ApoA-I mimetic peptide P2a by restoring cholesterol esterification
unmasks Apo A-I anti-inflammatory endogenous activity in vivo. J Pharmacol Exp Ther. 2011 Dec 13.
[Epub ahead of print] PubMed PMID: 22171091.
Pagina 18/18 - Curriculum vitae del
Prof. Cirino Giuseppe